マントル細胞リンパ腫の世界市場-2022-2029年

市場力学

主な原動力は、マントル細胞リンパ腫の有病率の増加と、ヘルスケア分野における研究開発活動の活発化により、製品パイプラインが充実していることです。

現在進行中の研究開発活動の存在が、市場成長の原動力になると予想されます。

有望なマントル細胞リンパ腫のパイプラインは、予測期間中の市場成長を促進するでしょう。例えば、アストラゼネカは、新規薬剤による治療を受けたマントル細胞リンパ腫患者の前向き疾患登録を後援しており、2024年3月20日に完了すると予想されています。ソウル大学病院がスポンサーとなり、2025年6月に開始が予定されている再発・難治性マントル細胞リンパ腫患者におけるボルテゾミブ、シタラビン、デキサメタゾンの効果を評価する第2相試験、プレコグ社がスポンサーとなった再発・難治性マントル細胞リンパ腫におけるイキサゾミブとイブルチニブの第I/II相試験、など。また、武田薬品との共同研究であり、2024年12月に完了する予定である、マントル細胞リンパ腫と新たに診断された患者を対象としたixazomib維持療法の多施設共同第II相試験（Kosin University Gospel Hospital、武田薬品の協賛、発売予定：2022年12月）は、2022年に完了する予定であります。

高い開発コストと副作用の発現が、世界のマントル細胞リンパ腫市場の成長を妨げると予想されます。

しかし、貧血、好中球減少、下痢などの薬剤の重篤な副作用が市場成長を抑制しています。

産業分析。

マントル細胞リンパ腫の世界市場レポートでは、Porter`s Five Force、イノベーション、新製品発表、価格分析、パイプライン分析など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19は、世界のマントル細胞リンパ腫市場に大きな影響を与えています。COVID-19の封じ込めプロトコルのため、多くの市場プレイヤーのサプライチェーンが混乱し、原材料の不足を引き起こし、需給連鎖が乱れました。さらに、社会化規制のため、定期的な健康診断が難しく、マントル細胞リンパ腫の患者のほとんどが発見されず、パンデミック中の世界のマントル細胞リンパ腫市場の成長にマイナスの影響を及ぼしました。

マントル細胞リンパ腫の世界市場レポートでは、約40以上の市場データ表、45以上の図表、200ページ（概算）範囲でのアクセスを提供することになります。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 研究開発
    • 癌患者の増加
  • 抑制要因
    • 高い開発コスト
    • 副作用
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 治療法タイプ別

• 標的治療
• 化学療法
• 放射線療法
• その他

第8章 投与経路別

• 経口
• 注射剤

第9章 エンドユーザー別

• 病院・クリニック
• がん研究センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第12章 企業プロファイル

• Kite Pharma, Inc.（Gilead Sciences, Inc.）
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• F. Hoffman La Roche Ltd
• Abbvie, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Amgen, Inc.
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca Plc
• Johnson and Johnson

第13章 DataM

Market Overview

Mantle Cell Lymphoma Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7% during the forecast period (2022-2029).

Mantle cell lymphoma (MCL) is a rare type of blood cancer due to the excessive growth of lymphocytes. Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas, which occur due to the formation of tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver.

Market Dynamics

The major driving forces are the growing prevalence of mantle cell lymphoma and increasing research & development activities in the healthcare sector resulting in a robust product pipeline.

The presence of ongoing research and development activities is expected to drive market growth.

The promising mantle cell lymphoma pipeline will drive market growth over the forecast period. For instance, AstraZeneca has sponsored a prospective disease registry of patients with mantle cell lymphoma treated with novel agents and is anticipated to be completed on March 20, 2024; a Phase 2 trial to assess the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma, sponsored by Seoul National University Hospital and is anticipated to be launched in June 2025, a Phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma sponsored by PrECOG, LLC. In collaboration with Takeda and anticipated to be completed in December 2024 and a Multicenter Phase II study of ixazomib maintenance in patients with newly diagnosed mantle cell lymphoma, Kosin University Gospel Hospital, in collaboration with Takeda sponsored and expected launch is in December 2022.

The high development cost and the onset of side effects are expected to hinder global mantle cell lymphoma market growth.

However, serious side effects of drugs like anemia, neutropenia, and diarrhea are restraining market growth.

Industry analysis.

The global mantle cell lymphoma market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global mantle cell lymphoma market. Because of the COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials, which disturbed the supply and demand chain. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.

Segment Analysis

The targeted therapy segment is assumed to command the Mantle Cell Lymphoma market throughout the forecast period (2022-2029).

The targeted therapy segment is expected to grow rapidly over the forecast period (2022-2029). Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent's ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD. For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.

Geographical Analysis

The North American region holds the largest market share of the global Mantle Cell Lymphoma market.

North America dominated the global mantle cell lymphoma market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of key market players in North America and their hold over the global market with increasing research and development activities. For instance, on July 24, 2020, a U.S.-based company, Kite, A Gilead Company. LLS secured the approval for its brexucabtagene autoleucel (formerly KTE-X19, now branded as Tecartus) as the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with MCL. Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market. According to the U.S. Census Bureau estimation, over 54 million adults aged 65 and older in 2020 made up 16.5% of the total United States population, estimated to reach 85.7 million by 2050, accounting for 20% of the total United States Population.

Competitive Landscape

The major players operating in the global mantle cell lymphoma market are F. Hoffman La Roche Ltd, Abbvie, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, and Johnson and Johnson. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the mantle cell lymphoma market. For instance, on 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma. Also, on July 27, 2021, AbbVie and Calico announced the extension of collaboration focused on aging and age-related diseases.

Kite Pharma, Inc. (Gilead Sciences, Inc.)

Overview:

Kite Pharma is a branch of Gilead Sciences, Inc. Kite Pharma was established in 2009 with its headquarters in California, United States. Kite Pharma is a leading American biotechnology company involved in developing cancer immunotherapy products that are majorly focused on the genetically-engineered autologous T cell therapy with chimeric antigen receptors.

Product Portfolio:

The Kite Pharma, Inc. (Gilead Sciences, Inc.) product portfolio for mantle cell lymphoma contains Tecartus.

The global mantle cell lymphoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Research and Development
    • 4.1.1.2. Increasing Prevalence of Cancer Cases
  • 4.1.2. Restraints
    • 4.1.2.1. The High Development Cost
    • 4.1.2.2. Side Effects
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Therapy Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment
  • 7.1.2. Market Attractiveness Index, By Therapy Type Segment
• 7.2. Targeted Therapy
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Chemotherapy
• 7.4. Radiotherapy
• 7.5. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
• 8.2. Oral
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Injectable

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User Segment
• 9.2. Hospitals and Clinics
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Cancer Research Center
• 9.4. Other

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. F. Hoffman La Roche Ltd
• 12.3. Abbvie, Inc.
• 12.4. Celgene Corporation
• 12.5. Eli Lilly and Company
• 12.6. Amgen, Inc.
• 12.7. Takeda Pharmaceutical Co. Ltd
• 12.8. AstraZeneca Plc
• 12.9. Johnson and Johnson

LIST NOT EXHAUSTIVE

13. DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us